Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation botulinumtoxinA (RelabotulinumtoxinA) for the Treatment of Glabellar Lines (frown) and Lateral Canthal Lines (crow’s Feet)
Galderma announced today at the Vegas Cosmetic Surgery & Aesthetic Dermatology meeting, topline results from two phase III clinical studies (NCT04249583, NCT04249687) demonstrating that RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, improves both glabellar and lateral canthal lines with a rapid onset of action and a long duration up to six months.1,2
Developed by Galderma, RelabotulinumtoxinA is a highly-active, innovative, complex-free, and ready-to-use liquid botulinum toxin A with a proprietary strain and manufactured using a state-of-the-art, unique process.1,3 RelabotulinumtoxinA is designed as a liquid, avoiding the traditional requirement to reconstitute from powder, eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. The READY (RElabotulinumtoxin Aesthetic Development StudY) phase III clinical program is composed of four phase III clinical trials which enrolled more than 1,900 participants.
"We developed this innovative neuromodulator to respond directly to the needs of healthcare professionals and the expectations of patients who are looking for a safe, effective, long-lasting treatment that offers consistency in results for frown lines and crow’s feet, which can have a significant impact on patients’ self-esteem and well-being. We are looking forward to submitting the data to U.S. and global authorities as part of the next step in bringing this potential, new treatment to patients.”
Baldo Scassellati Sforzolini, M.D.
Global Head of Research & Development
Both studies met their primary endpoint, demonstrating a significant ≥2-grade composite improvement (as assessed by both subject and investigator) in glabellar line severity and lateral canthal line severity vs. placebo at Month 1, with rapid onset of action and up to six-month duration of action.
The first clinical study, READY-1, was a multicenter, randomized, double-blind, placebo-controlled, phase III trial of RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines (frown lines) in 300 participants followed for six months.1 Results from READY-1 showed that RelabotulinumtoxinA significantly reduced glabellar line severity and was well tolerated.1
READY-1 met its primary endpoint for participants with moderate-to-severe glabellar lines – the response to RelabotulinumtoxinA was significantly higher than placebo after one month (82.9% vs. 0%; P<0.001).1
In the trial, RelabotulinumtoxinA had a rapid onset of effect (median 2 days, 39% of participants reported an effect on Day 1) and the effects were long-lasting, persisting for up to six months. The median time to return to baseline severity was >24 weeks (end of study).1
Participant satisfaction with treatment was high for RelabotulinumtoxinA vs. placebo. At Month 1, 97% of participants were satisfied with the outcome of treatment and 86% remained satisfied at Month 6.1 Treated participants were also highly satisfied with how natural they looked (97% at Month 1, 88% at Month 6).1
The second study, READY-2, was a multicenter randomized,double-blind, placebo-controlled, phase III trial of RelabotulinumtoxinA for the treatment of moderate-to-severe lateral canthal lines (crow’s feet).2 Results from the six-month study, involving 303 participants, showed that treatment with RelabotulinumtoxinA improved lateral canthal lines, with high participant satisfaction and a rapid onset of effect.2
READY-2 met its primary endpoint with the response among those participants receiving treatment significantly higher than placebo (51.8% vs. 1.4%, P<0.001).2
The onset of effect was rapid (median 2 days, 34% of participants reported onset of effect by Day 1) and the effect was long-lasting, up to six months. The median time to return to baseline severity was 173 days (24.7 weeks).2
Safety and tolerability profile
In both studies, RelabotulinumtoxinA was well tolerated.1,2 All treatment-related adverse events were mild-to-moderate, non-serious and transient.1,2
In READY-1, 3.6% of treated participants (0%, placebo) experienced a treatment-related adverse event; the most common was headache.1 In READY-2, treatment-related adverse events occurred in 6.1% of treated participants (5.5%, placebo) and the most common was injection-site bruising.2
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that spans the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
1. Shridharani, S., et al. Treatment of moderate-to-severe glabellar lines with RelabotulinumtoxinA, a new liquid botulinum toxin: Clinical efficacy and safety results from the READY-1 Phase III trial. Poster presented at Vegas Cosmetic Surgery & Aesthetic Dermatology 2022, Las Vegas, NV, June 8-11, 2022
2. Ibrahim, SF, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, a new liquid botulinum toxin: Clinical efficacy and safety results from the READY-2 Phase III trial. Poster presented at Vegas Cosmetic Surgery & Aesthetic Dermatology 2022, Las Vegas, NV, June 8-11, 2022.
3. Liljegren Sundberg, Å and Ståhl, U. Relabotulinum toxin – a novel, high purity BoNT-A1 in liquid formulation. Poster presented at TOXINS, virtual online event, January 16-17, 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
+41 76 315 26 50
Global Franchise Communications
+41 76 261 64 41
Corporate Communications Director
+41 79 529 59 85
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hy Stor Energy Strategic Partnership with Key Gulf Coast Port Becomes First to Deliver Renewable Hydrogen Access for Manufacturing, Industrial Applications, Port Operations and Long Duration Energy Storage29.6.2022 16:00:00 EEST | Press release
Hy Stor Energy LP (Hy Stor Energy), a company pioneering renewably produced green hydrogen and energy storage at scale in Mississippi, announced today a strategic partnership with the Hancock County Port and Harbor Commission (HCPHC) to provide zero-carbon, zero-methane hydrogen to Port Bienville Industrial Park and Stennis International Airport, accelerating the decarbonization of land, air, sea, and space. Through this partnership, Port Bienville will be the first port in the Gulf Region to integrate renewable hydrogen as a fuel into its operations. During the first phase of the partnership, the hydrogen hub is expected to produce an estimated 350 tons/day (320,000 kg/day) of renewable hydrogen and store more than 71,000 tons (69 million kg) of hydrogen in underground salt caverns. The existing Port Bienville infrastructure will expand to better enable decarbonization efforts and will be in a premium location to allow for new manufacturing of circular hydrogen infrastructure – the fi
Medidata Announces Rapid Expansion of its Sensor Cloud Network with the Addition of 10 Health Technology Innovators29.6.2022 16:00:00 EEST | Press release
Medidata, a Dassault Systèmes company, announced 10 highly innovative organizations have joined its groundbreaking Sensor Cloud Network. AliveCor, Aural Analytics, Biobeat, Blue Spark Technologies, Glooko, Indie Health, University of Arizona, Carnegie Mellon University, University of Rochester, and University of Vermont are now part of the first cross-sector collaboration focused on solving the challenges related to sensor integrations, standardization of sensor data, and the development of novel digital biomarkers and algorithms. These will help to create new digital endpoints that could translate into more effective treatments and better healthcare for patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005239/en/ The Sensor Cloud Network, which includes contract research organizations (CROs), device manufacturers, drug and vaccine developers, analytics companies, and academic institutions, creates opportunities
Western Union Highlights ESG Progress and Recognitions Received29.6.2022 15:00:00 EEST | Press release
The Western Union Company (NYSE: WU) today released its 2021 Environmental, Social and Governance (ESG) Report, spotlighting the Company’s ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005138/en/ Western Union's 2021 ESG report spotlights the Company’s ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.(Photo: Business Wire) “People are drawn to work for and do business with companies that make an impact,” said Devin McGranahan, Chief Executive Officer. “This year’s report shows that Western Union continues to make solid progress on our ESG journey, which in turn enables us to effect even more positive change in the communities we serve. I’m proud to work with colleagues who bring their best every day to improve the lives of our customers and communities around the world.” 2021 ESG Highlights
Pyramid Analytics Wins 2022 Ventana Research Digital Innovation Award in Analytics Category29.6.2022 15:00:00 EEST | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today announced that the company won a 2022 Ventana Research Digital Innovation Award. The company’s Pyramid Decision Intelligence Platform was selected over finalists Qlik Active Intelligence and H2O AI Cloud in the Analytics category of the 15th edition of the respected analyst firm’s awards program. The award is given to the technology vendor that best exemplifies innovation in any use or application of analytics across business and/or IT. The Business Intelligence and Analytics segment of the global software market is highly competitive. There are an estimated 120 vendors in the space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005330/en/ Pyramid Analytics, a pioneering decision intelligence platform provider, won a 2022 Ventana Research Digital Innovation Award. The Pyramid Decision Intelligence Platform was selected over finali
GPS Announces New Senior Leadership Changes29.6.2022 14:14:00 EEST | Press release
Global Processing Services (GPS), a leading global payment technology platform, has today announced the promotion of Joanne Dewar to Vice Chair. Kevin Schultz has also been appointed as Chief Executive Officer, effective immediately. Joanne will maintain her position on the GPS board, where she will focus on the group’s growth and global profile, and continue to work alongside Chair, Gene Lockhart, in a newly created Office of the Chair. Joanne had been CEO at GPS for over four years and was instrumental in scaling the company and securing investment from arguably the most impressive consortium in the payments industry. Kevin brings a wealth of executive leadership experience in the payments and digital banking industry to his new role as CEO, where he will primarily focus on strategy and execution. Most recently, Kevin served as Fiserv’s Group President of the Digital Banking. Prior to Fiserv, Kevin served as President, Global Financial Services at First Data, following nearly 16 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom